Literature DB >> 29565672

A radiogenomic analysis of hepatocellular carcinoma: association between fractional allelic imbalance rate index and the liver imaging reporting and data system (LI-RADS) categories and features.

Alessandro Furlan1, Omar Almusa1, Robinson K Yu1,2, Hersh Sagreiya1,3, Amir A Borhani1, Kyongtae T Bae1, J Wallis Marsh4,5.   

Abstract

OBJECTIVE: To evaluate the association between the liver imaging reporting and data system (LI-RADS) categories and features and the fractional allelic imbalance (FAI) rate index of hepatocellular carcinoma (HCC).
METHODS: The institutional review board approved this retrospective study. Medical records collected between January 2008 and December 2013 were reviewed to find patients with histologically confirmed HCC, FAI analysis, and CT or MR imaging of the liver. The final population included 71 patients (54 males, 17 females). Three radiologists reviewed the images using the LI-RADS v. 2014. The association between FAI and LI-RADS categories and features was tested using the Spearman's rank correlation coefficient (rho) and the Wilcoxon rank-sum test [low FAI (<40%) vs high FAI (≥40%)]. A p value < 0.007 was used as the threshold for statistical significance after application of the Bonferroni correction for multiple comparisons.
RESULTS: HCCs were classified as LR-3 (n = 4), LR-4 (n = 22), and LR-5 (n = 45). There was a positive correlation (rho = 0.264) between FAI rate index and LI-RADS category, although not statistically significant after Bonferroni correction (p = 0.024). 14 of the 20 (70%) HCCs with high FAI (≥40%) were categorized as LR-5, 6/20 (30%) as LR-4 and none as LR-3 (p = 0.377). Among the evaluated LI-RADS imaging features, only lesion size showed a statistically significant different distribution in tumors with high FAI compared to those with low FAI. HCCs with FAI ≥40% were larger (56 ± 42 mm) compared to those with FAI <40% (36 ± 30 mm; p = 0.005).
CONCLUSION: There was a positive correlation, although not statistically significant, between the LI-RADS diagnostic categories and the FAI rate of HCC. Tumors with high FAI were larger compared to those with low FAI. Advances in knowledge: HCCs with high (≥40%) FAI are larger compared to those with low (<40%) FAI.

Entities:  

Mesh:

Year:  2018        PMID: 29565672      PMCID: PMC6223296          DOI: 10.1259/bjr.20170962

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  17 in total

1.  Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study.

Authors:  Kathryn J Fowler; An Tang; Cynthia Santillan; Mythreyi Bhargavan-Chatfield; Jay Heiken; Reena C Jha; Jeffrey Weinreb; Hero Hussain; Donald G Mitchell; Mustafa R Bashir; Eduardo A C Costa; Guilherme M Cunha; Laura Coombs; Tanya Wolfson; Anthony C Gamst; Giuseppe Brancatelli; Benjamin Yeh; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-01       Impact factor: 11.105

2.  Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm.

Authors:  Maxime Ronot; Olivia Fouque; Maxime Esvan; Jérome Lebigot; Christophe Aubé; Valérie Vilgrain
Journal:  J Hepatol       Date:  2017-12-21       Impact factor: 25.083

Review 3.  LI-RADS categories: concepts, definitions, and criteria.

Authors:  Cynthia Santillan; Victoria Chernyak; Claude Sirlin
Journal:  Abdom Radiol (NY)       Date:  2018-01

4.  Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers.

Authors:  Myron Schwartz; Igor Dvorchik; Sasan Roayaie; M Isabel Fiel; Sidney Finkelstein; J Wallis Marsh; John A Martignetti; Josep M Llovet
Journal:  J Hepatol       Date:  2008-05-20       Impact factor: 25.083

5.  Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival.

Authors:  J Wallis Marsh; Sydney D Finkelstein; Anthony J Demetris; Patricia A Swalsky; Eizaburo Sasatomi; Andriy Bandos; Michael Subotin; Igor Dvorchik
Journal:  Liver Transpl       Date:  2003-07       Impact factor: 5.799

Review 6.  Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging.

Authors:  Aaron M Rutman; Michael D Kuo
Journal:  Eur J Radiol       Date:  2009-03-19       Impact factor: 3.528

7.  Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma.

Authors:  Michael D Kuo; Jeremy Gollub; Claude B Sirlin; Clara Ooi; Xin Chen
Journal:  J Vasc Interv Radiol       Date:  2007-07       Impact factor: 3.464

8.  A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma.

Authors:  Sudeep Banerjee; David S Wang; Hyun J Kim; Claude B Sirlin; Michael G Chan; Ronald L Korn; Aaron M Rutman; Surachate Siripongsakun; David Lu; Galym Imanbayev; Michael D Kuo
Journal:  Hepatology       Date:  2015-07-01       Impact factor: 17.425

9.  Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results.

Authors:  Bachir Taouli; Yujin Hoshida; Suguru Kakite; Xintong Chen; Poh Seng Tan; Xiaochen Sun; Shingo Kihira; Kensuke Kojima; Sara Toffanin; M Isabel Fiel; Hadassa Hirschfield; Mathilde Wagner; Josep M Llovet
Journal:  Eur Radiol       Date:  2017-04-24       Impact factor: 7.034

10.  Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging.

Authors:  Stefanie J Hectors; Mathilde Wagner; Octavia Bane; Cecilia Besa; Sara Lewis; Romain Remark; Nelson Chen; M Isabel Fiel; Hongfa Zhu; Sacha Gnjatic; Miriam Merad; Yujin Hoshida; Bachir Taouli
Journal:  Sci Rep       Date:  2017-05-26       Impact factor: 4.996

View more
  4 in total

Review 1.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

Review 2.  Radiomics of hepatocellular carcinoma.

Authors:  Sara Lewis; Stefanie Hectors; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2021-01

3.  Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.

Authors:  Daniel R Ludwig; Tyler J Fraum; Roberto Cannella; David H Ballard; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2019-06

Review 4.  Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response.

Authors:  Amir A Borhani; Roberta Catania; Yuri S Velichko; Stefanie Hectors; Bachir Taouli; Sara Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.